Karyopharm Therapeutics (NASDAQ:KPTI) Stock Price Crosses Below 200 Day Moving Average - Time to Sell?

Shares of Karyopharm Therapeutics Inc. (NASDAQ:KPTI - Get Free Report) crossed below its two hundred day moving average during trading on Tuesday . The stock has a two hundred day moving average of $0.79 and traded as low as $0.60. Karyopharm Therapeutics shares last traded at $0.62, with a volume of 924,826 shares.

Analysts Set New Price Targets

Several research firms have weighed in on KPTI. StockNews.com downgraded Karyopharm Therapeutics from a "buy" rating to a "hold" rating in a research note on Friday, November 22nd. Piper Sandler increased their target price on Karyopharm Therapeutics from $4.00 to $5.00 and gave the company an "overweight" rating in a research report on Wednesday, November 6th. Finally, HC Wainwright reiterated a "buy" rating and set a $7.00 target price on shares of Karyopharm Therapeutics in a research report on Wednesday, January 15th. One research analyst has rated the stock with a hold rating and four have given a buy rating to the company's stock. According to data from MarketBeat, Karyopharm Therapeutics currently has a consensus rating of "Moderate Buy" and an average target price of $5.00.

Karyopharm Therapeutics Trading Down 4.0 %

The stock has a market capitalization of $79.63 million, a P/E ratio of -0.55 and a beta of 0.06. The business has a 50-day moving average price of $0.69 and a 200 day moving average price of $0.78.

Karyopharm Therapeutics (NASDAQ:KPTI - Get Free Report) last released its quarterly earnings results on Tuesday, November 5th. The company reported ($0.26) earnings per share for the quarter, beating the consensus estimate of ($0.27) by $0.01. The company had revenue of $38.78 million for the quarter, compared to analysts' expectations of $37.86 million. During the same quarter in the previous year, the company posted ($0.30) EPS. On average, sell-side analysts predict that Karyopharm Therapeutics Inc. will post -0.83 earnings per share for the current fiscal year.

Institutional Trading of Karyopharm Therapeutics

Several hedge funds and other institutional investors have recently bought and sold shares of KPTI. GSA Capital Partners LLP increased its stake in Karyopharm Therapeutics by 80.6% in the third quarter. GSA Capital Partners LLP now owns 1,775,700 shares of the company's stock worth $1,474,000 after purchasing an additional 792,283 shares during the period. Geode Capital Management LLC increased its stake in Karyopharm Therapeutics by 3.3% in the third quarter. Geode Capital Management LLC now owns 1,355,392 shares of the company's stock worth $1,125,000 after purchasing an additional 43,856 shares during the period. AQR Capital Management LLC increased its stake in Karyopharm Therapeutics by 494.5% in the second quarter. AQR Capital Management LLC now owns 748,020 shares of the company's stock worth $649,000 after purchasing an additional 622,194 shares during the period. Cubist Systematic Strategies LLC purchased a new stake in Karyopharm Therapeutics in the second quarter worth $494,000. Finally, FMR LLC increased its stake in Karyopharm Therapeutics by 26.1% in the third quarter. FMR LLC now owns 369,723 shares of the company's stock worth $307,000 after purchasing an additional 76,510 shares during the period. Hedge funds and other institutional investors own 66.44% of the company's stock.

Karyopharm Therapeutics Company Profile

Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).